NCT06459180 2026-04-13
TroFuse-020
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
26 trialsNCT07418749 2026-04-06
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT04697628 2026-02-24
innovaTV 301
Seagen Inc.
Phase 3 Completed
NCT02487095 2025-04-13
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
NCT01076400 2023-09-18
MK-1775-008
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT02866006 2022-10-12
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
Cellid Co., Ltd.
Phase 1/2 Completed
NCT04943627 2022-10-05
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
Phase 3 Withdrawn
NCT01266447 2019-08-08
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00803062 2019-07-23
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00087126 2019-01-08
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
GOG Foundation
Phase 2 Completed
NCT00064077 2018-10-17
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
GOG Foundation
Phase 3 Completed
NCT00257816 2018-02-05
Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma
University of California, Irvine
Phase 2 Completed
NCT00287911 2017-12-02
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT02348398 2016-08-16
Phase II Study of Pazopanib and Topotecan in Cervical Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00807079 2014-10-29
Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer
ARCAGY/ GINECO GROUP
Phase 1/2 Completed
NCT00548418 2014-08-01
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
Washington University School of Medicine
Phase 2 Completed
NCT00003065 2014-01-06
Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix
National Cancer Institute (NCI)
Phase 2 Completed
NCT00523432 2013-09-05
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
University of Chicago
Phase 1 Completed
NCT00003945 2013-05-27
Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
GOG Foundation
Phase 3 Completed
NCT00276796 2013-05-27
Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
GOG Foundation
Phase 2 Completed
NCT00842452 2013-04-05
Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00320983 2010-01-07
Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer
University of New Mexico
Phase 1 Completed
NCT00315861 2009-01-23
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00826891 2009-01-22
Study of Cisplatin in Cervical Cancer Stage IVB
Chinese Anti-Cancer Association
Phase 2 Unknown
NCT00322920 2008-02-15
Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer
University of Alabama at Birmingham
Phase 1 Terminated